Burden of Illness in Geographic Atrophy: A Study of Vision-Related Quality of Life and Health Care Resource Use
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Purpose: To gain comprehensive information on the burden of illness due to geographic atrophy (GA). Methods: This cross-sectional study with a retrospective chart review involved patients aged ≥70 years with physician-confirmed bilateral symptomatic GA due to age-related macular degeneration (GA group), as well as patients of similar age with no ophthalmic condition that in the opinion of the investigator affected visual function (non-GA group). Data relating to patients’ current disease status and sociodemographics were self-reported on patient questionnaires at study entry and extracted from patient charts. Historical data on health care resource utilization (HCRU) were also collected via patient questionnaires and retrospective chart review (GA group only). Overall vision-related functioning and quality of life (QoL) were compared between the GA and non-GA groups using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) composite and subscales, and change in vision over the past year was assessed using the Global Rating of Change Scale. Results: Vision-related functioning and QoL were poorer in patients with vs without GA (n=137 vs 52), as demonstrated by significantly lower NEI-VFQ-25 composite score (mean, 53.1 vs 84.5 points, respectively; P <0.001), as well as lower subscale scores for near activities, distance activities, dependency, driving, social functioning, mental health, role difficulties, color vision, and peripheral vision. Substantially more patients with GA than without GA reported worsening in vision over the past year (82% vs 25%, respectively; odds ratio, 13.55; P <0.001). In the GA group, associated mean annual costs for direct ophthalmological resource use per patient amounted to €1772 (mostly for tests/procedures), and for indirect ophthalmological resource use, €410 (mostly for general practitioner visits). Conclusion: Patients with GA experience a poorer level of vision-related function and QoL than their peers, especially in relation to driving. GA is also associated with notable HCRU/associated costs, mostly direct costs attributed to diagnostic tests/procedures. Keywords: burden of illness, geographic atrophy, vision-related quality of life, health care resource utilization, visual function, health care costs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Direct medical costs were reported in all studies [44, 46, 47] and were expressed as mean annual costs per patient in two [44, 46], ranging from $496 to $2,633.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Direct non-medical costs related to formal care and assistive technologies were estimated at $620 per patient per year in one multi-country study led by Patel et al. [46].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given the absence of treatment options for dry AMD at the time of the studies’ publication, no treatment cost related to the condition was considered in any of the three studies.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three studies [44, 46, 47] estimated costs associated with dry AMD and more specifically geographic atrophy, the advanced form of dry AMD (Fig. 4 and Supplementary Table 4).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While ophthalmological care was accounted for in all studies, costs pertaining to care for depression and falls was explicitly considered in one multi-country study [46].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“The incidence of GA increases exponentially with age, and as the population ages, the prevalence of the disease is expected to rise.(4,6) GA comprises a spectrum of heterogeneous, phenotypically distinct forms, in which visual function is determined by the remaining area in relation to the fovea.”
BackgroundJaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Retinal nerve fiber layer analysis in the diagnosis of glaucoma
Zangwill, L. M., & Bowd, C. (2006) · Current Opinion in Ophthalmology · doi:10.1097/01.icu.0000193079.55240.18 · Cited by 595 · cited 2×
“Advanced AMD has been estimated to cause a 63% decrease in the average patient’s quality of life (QoL), which is comparable to the effect of end-stage prostate cancer or catastrophic stroke on QoL.13 However, there is sparse knowledge of the impact of GA on patients’ QoL, as well as on society and health care resource…”
MethodInfluentialThe Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Fleckenstein, M., Mitchell, P., Freund, K. B., Sadda, S., Holz, F. G., Brittain, C., Henry, E. C., & Ferrara, D. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.038 · Cited by 561
Holz, F. G., Strauss, E. C., Schmitz-Valckenberg, S., & van Lookeren Campagne, M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.023 · Cited by 402
Rudnicka, A. R., Jarrar, Z., Wormald, R., Cook, D. G., Fletcher, A., & Owen, C. G. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.09.027 · Cited by 394
Sunness, J. S., Gonzalez-Baron, J., Applegate, C. A., Bressler, N. M., Tian, Y., Hawkins, B., Barron, Y., & Bergman, A. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90340-8 · Cited by 348 · cited 10×
“Differences in Vision-Related Functioning and QoL Between the GA and Non-GA Groups Patients with GA had poorer vision-related functioning and QoL than those without GA. Patients in the GA group had a significantly lower mean (SD) NEI-VFQ-25 composite score than those in the non-GA group (53.1 [19.05] vs 84.5 [6.55] po…”
ResultInfluentialKaiser, P. K. (2009) · PubMed Central · Cited by 315
Sunness, J. S., Rubin, G. S., Applegate, C. A., Bressler, N. M., Marsh, M. J., Hawkins, B. S., & Haselwood, D. (1997) · Ophthalmology · doi:10.1016/s0161-6420(97)30079-7 · Cited by 309 · cited 11×
“Differences in Vision-Related Functioning and QoL Between the GA and Non-GA Groups Patients with GA had poorer vision-related functioning and QoL than those without GA. Patients in the GA group had a significantly lower mean (SD) NEI-VFQ-25 composite score than those in the non-GA group (53.1 [19.05] vs 84.5 [6.55] po…”
BackgroundResultInfluential
Research works printed but not linked: 1
- [14]Orr S. Disease burden associated with geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016; 57(12): 21.
Cited by
Heier, J. S., Lad, E. M., Holz, F. G., Rosenfeld, P. J., Guymer, R. H., Boyer, D., Grossi, F., Baumal, C. R., Korobelnik, J.-F., Slakter, J. S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01520-9 · Cited by 520
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
Bakri, S. J., Bektas, M., Sharp, D. A., Luo, R. T., Sarda, S. P., & Khan, S. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5-a.s2 · Cited by 73
Rowe, L. W., & Ciulla, T. A. (2024) · Genes · doi:10.3390/genes15060720 · Cited by 53
“…irreversible visual impairment in individuals aged 60 The burden of illness associated with geographic atrophy is considerable, greatly diminishing the quality of life for both patients and their caregivers [55,56]. years or older, with approximately 5 million people affected by GA globally [9,54].”
BackgroundEconomic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US
Paudel, N., Brady, L., Stratieva, P., Galvin, O., Lui, B., Brande, I. V. D., Malkowski, J., Rebeira, M., MacAllister, S., O’Riordan, T., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.4401 · Cited by 44
Wykoff, C. C., Hershberger, V. S., Eichenbaum, D. A., Henry, E. C., Younis, H. S., Chandra, P., Yuan, N., Solloway, M. J., & DePaoli, A. M. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.08.018 · Cited by 31
Humanistic and Economic Burden of Geographic Atrophy: A Systematic Literature Review
Sarda, S. P., Heyes, A., Bektas, M., Thakur, T., Chao, W., Intorcia, M., Wronski, S. L., & Jones, D. L. (2021) · Clinical ophthalmology · doi:10.2147/opth.s338253 · Cited by 29
“In Europe, a retrospective chart review study investigated health-care resource use among patients in the UK, Germany, Ireland, and Canada with bilateral symptomatic GA versus a non-GA control group.(22) The annualized total cost, consisting of direct ophthalmic health-care resource use, was $2115 per patient with GA,…”
BackgroundSeeing Beyond Anatomy: Quality of Life with Geographic Atrophy
Caswell, D., Caswell, W., & Carlton, J. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00352-3 · Cited by 25
“I’m More Isolated, I Have to Depend on Others GA has a substantial effect on an individual’s mobility and independence [35, 49].”
BackgroundToro, M. D., Vidal-Aroca, F., Montemagni, M., Xompero, C., Fioretto, G., & Costagliola, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020518 · Cited by 19
“Patients with GA experience profound central and peripheral vision loss compared to their age-matched counterparts, and this affects a range of daily near, intermediate, and distance activities [7,8].”
BackgroundGupta, P., Fenwick, E., Man, R. E. K., Gan, A. T. L., Sabanayagam, C., Quek, D. Q. Y., Qian, C., Cheung, C. M. G., Cheng, C., & Lamoureux, E. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-12425-9 · Cited by 20
Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy
Danzig, C. J., Khanani, A. M., Kaiser, P. K., CHANG, M. A., Kovach, J. L., Lally, D. R., Rachitskaya, A. V., Sheth, V. S., Vajzovic, L. M., Clark, J., et al. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.04.023 · Cited by 26
Ehlers, J. P., McConville, C., Yordi, S. F., Cetin, H., Cakir, Y., Kalra, G., Amine, R., Whitney, J., Whitmore, V., Bonnay, M., et al. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.04.031 · Cited by 17
Visual Loss in Geographic Atrophy
Anegondi, N., Steffen, V., Sadda, S. R., Schmitz-Valckenberg, S., Tufail, A., Csaky, K. G., Lad, E. M., Kaiser, P. K., Ferrara, D., & Chakravarthy, U. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.11.017 · Cited by 17
Leng, T., Schwartz, J. J., Nimke, D., Gallivan, M. D., Fevrier, H. B., Rozario, N. L., & Schultz, N. M. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00583-y · Cited by 16
Geographic atrophy: Understanding the relationship between structure and function
Huang, A., Wu, Z., Ansari, G., von der Emde, L. A., Pfau, M., Schmitz-Valckenberg, S., Fleckenstein, M., Keenan, T. D. L., Sadda, S. R., Guymer, R. H., et al. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100207 · Cited by 15
Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Khanani, A. M., Danzig, C. J., Heier, J. S., Jaffe, G. J., Kaiser, P. K., Lally, D. R., Patel, S. S., Vajzovic, L. M., Weng, C. Y., Patel, H., et al. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.12.011 · Cited by 18
Ahluwalia, A., Shen, L. L., Bao, Y., Sun, M., Young, B. K., Park, M. M., & Priore, L. V. D. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05849-6 · Cited by 15
“While it is well established that the presence of GA is associated with a decline in VRQoL, little is known about the relationship between VRQoL and structural GA biomarkers [8, 9].”
BackgroundCorradetti, G., Karamat, A., Srinivas, S., Lindenberg, S., Velaga, S. B., Corvi, F., Attiku, Y., Nittala, M. G., Desai, D., Zhu, L., et al. (2024) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-024-06676-7 · Cited by 14
“Irreversible loss of visual function due to GA greatly affects patients’ quality of life, as it results in loss of independence and mobility [5–7].”
The Use of Neuroprotective Agents in Treating Geographic Atrophy
Scholl, H. P. N., Boyer, D. S., Giani, A., & Chong, V. N. (2021) · Ophthalmic Research · doi:10.1159/000517794 · Cited by 13
Geographic atrophy – Signs, symptoms, and quality of life
Nielsen, M. K., Hinnerskov, J. M. V., & Sørensen, T. L. (2023) · Acta Ophthalmologica · doi:10.1111/aos.15794 · Cited by 15
Impact of ocular trauma on vision-related quality of life
Shah, M., Shah, S., & Chandana, P. (2023) · Journal of Clinical Ophthalmology and Research · doi:10.4103/jcor.jcor_56_22 · Cited by 8
The Role of the Complement Pathway in Clinical Progression of Geographic Atrophy
Edmonds, R., Steffen, V., Honigberg, L. A., & Chang, M. C. S. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100301 · Cited by 8
Acar, D. E., Batıoğlu, F., Idil, A. M., Şahlı, E., & Göksülük, D. (2023) · Journal of Ophthalmology · doi:10.1155/2023/3389750 · Cited by 7
Yu, H. J., & Wykoff, C. C. (2021) · BioDrugs · doi:10.1007/s40259-021-00481-y · Cited by 7
Almuiña-Varela, P., García‐Quintanilla, L., Rodríguez‐Cid, M. J., Gil‐Martínez, M., Abraldes, M. J., Gómez‐Ulla, F., Estany‐Gestal, A., Alcántara, J. M., Fernández, M. I., & Fernández‐Ferreiro, A. (2024) · Pharmaceuticals · doi:10.3390/ph17020157 · Cited by 5
Bakri, S. J., Brinkmann, C. K., Mulvey, A., Steinberg, K., Katz, R., Vatsyayan, P., Sarda, S. P., & Holekamp, N. M. (2024) · Clinical ophthalmology · doi:10.2147/opth.s488559 · Cited by 4
“29 Further, findings from Patnaik et al indicated that composite subscale scoring for certain QoL related measures, such as role limitations, dependency, and driving, were numerically worse in bilateral patients with GA than those with unilateral GA. 18 While composite sub-scale scoring in Patel et…”
Khan, A. M., Shahnoor, S., Khan, H., Affendi, M., & Ghaddar, S. A. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000477 · Cited by 4
“Around one-quarter of cases of legal blindness in the United Kingdom and 20% of cases in North America are attributed to geographical atrophy([2]).”
BackgroundBakri, S. J., Amoaku, W. M. K., Altman, D. E., Quéré, S., Quilantan, J., Carpenter-Conlin, J., Sarda, S. P., Jones, D. L., & Nielsen, J. S. (2024) · Clinical ophthalmology · doi:10.2147/opth.s455984 · Cited by 5
“A conceptual model derived from patient and caregiver interview data documents the clinical, emotional, and financial burden of GA. Results of the interviews performed with the patients with GA and caregivers revealed significant impact of visual changes on patients (Figure 1a) and caregivers (Figure 1b).”
BackgroundResultInfluentialCrass, R. L., Prem, K., Gaudreault, F., Lusk, E., Ribeiro, R., Chapel, S. H., & Baumal, C. R. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13264 · Cited by 6
Alibhai, A. Y., Moult, E. M., Jamil, M. U., Raza, K., Morales, M. U., Ribeiro, R., Baumal, C. R., Fujimoto, J. G., & Waheed, N. K. (2025) · International Journal of Retina and Vitreous · doi:10.1186/s40942-024-00624-7 · Cited by 4
Morga, A., Chamberlain, C. X., Meyers, O. I., Roberts, C., Gaspar, L., & Su, J. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00667-3 · Cited by 8
“Several of these concepts were reported in previous studies by patients with GA, including distance, eye strain, fear, lack of independence, sadness, difficulty recognizing faces, and the inability to continue with visual hobbies like photography [9, 16, 21].”
BackgroundFaia, L. J., Ackert, J. M., Rodriguez, R., Sultan, A. A., Garey, C., Teneralli, R. E., & Ong, R. C.-Y. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03219-2 · Cited by 3
“A significant proportion of individuals with GA are registered as blind (e.g., 20% of cases in North America; 25% of cases in the UK), with a median time to blindness of approximately 6 years [11, 12].”
InfluentialConsideration of patient phenotypes in geographic atrophy due to age-related macular degeneration
Singh, R. P., Weng, C. Y., Kitchens, J. W., Quilantan, J., Schwartz, R., Baumal, C. R., & Goldberg, R. A. (2025) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2024-002105 · Cited by 2
Paudel, N., Moran, E. M., Stafford, S., McVicker, K., Stratieva, P., & Daly, A. (2025) · Clinical ophthalmology · doi:10.2147/opth.s525046 · Cited by 2
“Areas for considerations in the evidence summaries were identified based on the literature reviews 4,7,21–25 of the two topics and interviews with people living with GA (Supplementary Material Table S3).”
Sarda, S. P., Germain, G., Mahendran, M., Klimek, J., Cheng, W. Y., Luo, R., & Duh, M. S. (2024) · Clinical ophthalmology · doi:10.2147/opth.s475331 · Cited by 2
Geographic Atrophy Progression in Clinical Practice Before and After Pegcetacoplan Treatment
Cao, J. A., Zhou, A., Teagle, G. M., Baumann, L. M., Sahraravand, A., Wong, C. W., Zanet, S. I. D., Jovic, N., Steiner, P., Patel, S. B., et al. (2025) · Vision · doi:10.3390/vision9040095 · Cited by 1
“Patients with GA often experience a lower quality of life due to reduced visual acuity (VA), contrast sensitivity, and reading speed [8,9].”
Patel, S. S., Boyer, D., Loewenstein, A., Clark, J., Zhu, L., Tang, J., & Desai, D. (2026) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2025-002232 · Cited by 2
“7 8–13 The current standard of care for nAMD is intravit-real injections of vascular endothelial growth factor (VEGF) inhibitors.”
Validation of a novel multi-luminance shape discrimination test for assessment of functional vision
Emanuelli, A., Bakall, B., Lam, B. L., Wykoff, C. C., Liao, D. S., Bergstrom, L., Zak, V., Carlson, M. E., Kim, S.-H., Batabyal, S., et al. (2026) · Documenta Ophthalmologica · doi:10.1007/s10633-026-10086-x · Cited by 1
“…vision in patients occurs due to a variety of ocular diseases, including inherited retinal degenerations, as well as mass indications such as geographic atrophy (GA) [2], neovascular age-related macular degeneration (nAMD)[3], retinal vein occlusion (RVO) [4], and diabetic macular edema (DME) [5].”
Hallam, T. M., Gardenal, E., McBlane, F., Cho, G., Ferraro, L. L., Pekle, E., Lu, D., Carney, K., Wenden, C., Beadsmoore, H., et al. (2024) · medRxiv · doi:10.1101/2024.06.12.24308796 · Cited by 2
Hallam, T. M., Gardenal, E., McBlane, F., Cho, G., Ferraro, L. L., Pekle, E., Lu, D., Carney, K., Wenden, C., Beadsmoore, H., et al. (2024) · eLife · doi:10.7554/elife.99806.1 · Cited by 1
Assessing Macular Function: Should We Move Beyond Pragmatic Measures of Visual Acuity?
Munk, M. R., Lad, E. M., & Chakravarthy, U. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.01.006 · Cited by 1
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
“In terms of study perspective, one took a healthcare payer perspective [47], while the other two didn’t explicitly state the perspective but healthcare sector perspective is implied [44, 46].”
InfluentialSouto, F. M. S. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2022.tde-18042023-113322
Characterizing the Journey of Geographic Atrophy Patients in Routine Ophthalmic Practice
Gupta, U., Maatouk, C. M., Markle, J. C., Talcott, K. E., Singh, R. P., & Rachitskaya, A. V. (2024) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20240123-02
Hallam, T. M., Gardenal, E., McBlane, F., Cho, G., Ferraro, L. L., Pekle, E., Lu, D., Carney, K., Wenden, C., Beadsmoore, H., et al. (2024) · eLife · doi:10.7554/elife.99806
Alibhai, A. Y., Moult, E. M., Jamil, M. U., Raza, K., Morales, M. U., Ribiero, R., Baumal, C. R., Fujimoto, J. G., & Waheed, N. K. (2024) · Research Square · doi:10.21203/rs.3.rs-5183845/v1
“Geographic atrophy (GA), the late stage of non-exudative age-related macular degeneration, signi�cantly reduces quality of life 1,2 .”
Hallam, T. M., Gardenal, E., McBlane, F., Cho, G., Ferraro, L. L., Pekle, E., Lu, D., Carney, K., Wenden, C., Beadsmoore, H., et al. (2025) · eLife · doi:10.7554/elife.99806.2 · Cited by 1
Hark, L. A., Gorroochurn, P., Tang, H., Torres, D. R., Blackburn, B., Maruri, S. C., Diamond, D. F., Harizman, N., Wang, Q., Wang, Y., et al. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-024-06727-z
Falls and Fractures in Patients with Geographic Atrophy: A US Claims Data Analysis
Hu, A. Y. H., Teneralli, R. E., Rodriguez, R., Sultan, A. A., Garey, C., Ackert, J. M., & Ong, R. C.-Y. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03134-6
“Patients with GA also experience impaired quality of life compared to age-matched people without GA, particularly with regard to driving, resulting in decreased independence and increased reliance on carer support [12].”
Gunderson, I., Burale, A., Best, B. J., Tung, C. I., Huber, J., & Marsh, L. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01188-x
“Diffi-culties with driving, reading, watching television, and enjoying the theater were highlighted, along with broad impairment of quality of life, including in practical, psychological, emotional, and social domains [7–9, 11, 32–34].”
Prasad, M., Vitale, S., Agrón, E., Arunachalam, T., & Chew, E. Y. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.101022
Atrophy Advisor: A Clinical Tool for Dry Macular Degeneration With Geographic Atrophy
Kerwin, A. F., Perlman, E. M., & Browning, D. J. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.11.037 · Cited by 1
Kim, Y., Kim, Y. T., Kong, M., & Kim, J. H. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e63
“Patel et al. 27 found reduced National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) scores in GA patients, emphasizing limitations in daily functioning and increased healthcare utilization.”
Gene therapy for age-related macular degeneration: new prospects for vision restoration
Moshetova, L. K., & Soshina, M. M. (2025) · Pharmacogenetics and Pharmacogenomics · doi:10.37489/2588-0527-2025-4-18-28
Vision-Related Quality of Life in Geographic Atrophy
Anegondi, N., Lam, D., Guymer, R. H., Steffen, V., Cukras, C. A., Ferrara, D., & Wu, Z. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.04.019
Vingopoulos, F., Stevanovic, M., Razavi, P., Romano, F., Ding, X., Rodriquez, J., Baldwin, G. E., Choi, H., Katz, R., Husain, D., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101206 · Cited by 1
Prus-Ludwig, A., Wylęgała, A., Wylęgała, E., Kijonka, M., & Wowra, B. (2026) · Diagnostics · doi:10.3390/diagnostics16101555
“Age-related macular degeneration (AMD) remains a major public health problem and can lead to irreversible vision loss with a substantial impact on quality of life [132].”
Borkar, D., Arkin-Leydig, K., Toth, J., Patel, N., Abulon, D. J. K., & Shiozawa, A. (2026) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264261448421
“8,17,19,20 Understanding healthcare resource utilization in patients with GA is foundational to understanding the true cost of vision loss due to GA, a task that will become more imperative as GA prevalence is expected to increase as the global population ages.”
Baker, L., Rahhal, F. M., Gilbert, C. J., & Leng, T. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01459-1
“GA is associated with a reduced vision-related quality of life (QoL) and notable healthcare resource use-associated costs [13].”
Eichenbaum, D. A., Brown, D. M., Csaky, K. G., Danzig, C. J., Ehlers, J. P., Holz, F. G., Jaffe, G. J., Khanani, A. M., Lad, E. M., Verma, A., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101369
Patient and Physician Perspectives on Oral Treatment in Ophthalmology
Adelman, J., Barker, R., Best, B., Fisher, R., Mason, M., Udaondo, P., Garhöfer, G., & Csaky, K. G. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01496-w
Metadata
- Authors
- Patel, P. J., Ziemssen, F., Ng, E., Muthutantri, A., Silverman, D., Tschosik, E. A., & Cantrell, R. A.
- Affiliations
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Tübingen (DE)
- Waterford Institute of Technology (IE)
- IQVIA (United Kingdom) (GB)
- Roche (United Kingdom) (GB)
- Roche (United States) (US)
- Corresponding author
- Silverman, David
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- Volume 14
- Pages
- 15-28
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC6955611
- OpenAlex
- W2999121317
- Cited by
- 61
- References
- 38
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 16 · 2023: 9 · 2022: 4 · 2021: 5
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- F. Hoffmann-La Roche
- Nottingham University Hospitals NHS Trust
- University of Nottingham
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- geographic atrophy, age-related macular degeneration, disease burden, vision-related quality of life, healthcare resource utilization, health care costs, visual function, driving impairment, NEI VFQ-25, older adults
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.